Scienture posts 449% Q1 revenue growth and major gross margin expansion

Scienture Holdings (NASDAQ:SCNX) reported its financial results for the first quarter ended March 31, 2026, delivering dramatic top-line acceleration and margin optimization alongside key regulatory and pipeline updates.

The specialty pharmaceutical company generated total revenue of approximately $56,000 for the three-month period, representing an explosive 449% year-over-year increase compared to the $10,000 recorded during the first quarter of 2025.

The top-line surge fueled a major improvement in operational profitability at the manufacturing level.

Scienture's first-quarter gross profit climbed to approximately $54,000, triggering a massive gross margin expansion to 95.6%, up from just 6.6% in the prior-year period.

However, as the company aggressively scaled up its pipeline commercialization, clinical development, and administrative overhead, its net loss for the quarter widened to roughly $3.4 million, or $0.08 per share.

To fund this ongoing operational scaling without diluting equity, the Commack, New York-based firm finalized a crucial $11 million non-dilutive debt financing facility in early May.

The fresh capital is earmarked to drive immediate commercial launch activities for its core portfolio and provide an extended cash runway to support advanced research and development projects.

Operationally, Scienture achieved significant commercial and regulatory milestones for its leading drug candidates.

The company strengthened its intellectual property portfolio after receiving a third U.S. patent for Arbli (losartan potassium), the first FDA-approved, ready-to-use oral liquid suspension of the major hypertension medication.

The newly issued patent extends Arbli's expected market exclusivity through 2041.

Concurrently, Scienture enhanced its market path for REZENOPY, its 10 mg high-dose naloxone nasal spray approved for life-saving opioid overdose emergency treatment.

The company secured an Orange Book-listable patent for the device, providing long-term structural barriers against generic competition.

Furthermore, a series of recently activated Group Purchasing Organization (GPO) contracts successfully unlocked commercial access for REZENOPY across more than 5,000 healthcare institutions, hospitals, and emergency service networks nationwide.